Latest from Weill Cornell Sandra & Edward Meyer Cancer Center

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.
Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.
OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.  
Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.
Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.
Publication Bottom Border
Border Publication
x